Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo Mother’s goes subcontinental

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline launches Mother's Horlicks in India, a powdered drink mix for pregnant and breast-feeding mothers containing Martek's docosahexaenoic acid (DHA), Martek announces June 24. Mother's Horlicks is a "small part" of the Horlicks line, but Martek believes the product "will help set the stage" for expanded food and beverage applications for other products containing DHA. Martek recorded revenues of $41.9 mil. with earnings of $3.4 mil. in its most recent quarter, with results reflecting inefficiencies in the firm's arachidonic acid (ARA) production and a loss of sales due to a fire at a N.J. manufacturing facility (1"The Tan Sheet" May 24, 2004, In Brief)...

You may also be interested in...



Martek fire fallout

Fire at supplier DSM's Belvidere, N.J. ARA manufacturing plant will cause an estimated $5 mil. to $10 mil. loss in sales this quarter, Martek estimates in a May 17 statement. The fire shut down ARA production, which could be discontinued at the facility for a period of weeks. The full impact on the firm's revenues "will be determined once the extent of equipment damage is further assessed." Separately, Martek announced the filing of a universal SEC-shelf registration statement May 21 for debt securities, stock and warrants with a value of up to $200 mil...

With New Rare Blood Clot Warning, J&J COVID-19 Vaccine Rollout Resumes In EU

Similarities to AstraZeneca blood clots are clear, but more research needed before any ‘class effect’ conclusions can be drawn.

Hikma Resumes Launch Of Advair Rival

Hikma has restarted launch activities for its generic version of GSK’s Advair respiratory blockbuster in the US, after the FDA gave the go-ahead following approval of an ANDA amendment.

Topics

UsernamePublicRestriction

Register

PS096987

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel